" class="no-js "lang="en-US"> Rita Balice-Gordon - Medtech Alert
Tuesday, May 28, 2024
Rita Balice-Gordon

Rita Balice-Gordon

About Rita Balice-Gordon

Rita Balice-Gordon is Chief Scientific Officer, Muna Therapeutics, a biotech company transforming cutting edge science into impactful therapeutics for patients with neurodegenerative diseases representing tremendous unmet medical need around the globe. She is also an Entrepreneur-In-Residence at NovoSeeds, a VC firm that builds biotech companies based on innovative science to discover and develop future medicines. She is a Director on the Board of Collegium Pharmaceutical, a publicly traded company focused on bringing impactful pain management solutions to patients, and also a Director on the Board of Capsida Biotherapeutics, a biotech company bringing next-generation gene therapies to patients with rare and neurologic diseases. Rita serves on the Scientific Advisory Boards of several biotech companies developing innovative therapeutics for neurologic, psychiatric and rare diseases.

Related Story

Muna Therapeutics Appoints Dr. Niels Plath as Chief Scientific Officer

November 1 2021

Muna Therapeutics (“Muna“), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, […]

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

July 9 2021

Muna Therapeutics (“Muna”), pioneering the development of first-in-class small molecule therapeutics for neurodegenerative diseases, today […]